Literature DB >> 14519673

Treatment failure in invasive aspergillosis: susceptibility of deep tissue isolates following treatment with amphotericin B.

P J Paterson1, S Seaton, H G Prentice, C C Kibbler.   

Abstract

OBJECTIVES: To determine whether treatment failure in invasive aspergillosis (IA) is the result of resistance of Aspergillus spp. isolates to amphotericin B.
METHODS: Six Aspergillus fumigatus and six Aspergillus flavus isolates cultured from deep tissue biopsies in 11 patients with haematological malignancies during 1991-1998 were tested. A method based on the NCCLS M38-A broth microdilution method, with colorimetric determination of MICs, was used to determine the MICs of amphotericin B and itraconazole.
RESULTS: All A. fumigatus isolates were susceptible to amphotericin B (MIC 0.25-0.5 mg/L), as were three A. flavus isolates (MIC 1 mg/L), but three were less susceptible (MIC 2 mg/L). All isolates were susceptible to itraconazole (MIC 0.125-0.25 mg/L). All patients had been treated with amphotericin B, having received a median of 12 days of treatment when the tissue was obtained.
CONCLUSION: The difficulty in treating IA may not be because of the susceptibility of the isolates, but because of poor penetration of antifungal agents into infected tissue. Aspergillus spp. invade blood vessels causing thrombosis and tissue infarction, and therefore it may be difficult for antifungal drugs to exceed MICs in infected tissues. This highlights the need for different treatment strategies, such as surgery and the administration of cytokines.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14519673     DOI: 10.1093/jac/dkg434

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  20 in total

Review 1.  Aspergillus infections in transplant recipients.

Authors:  Nina Singh; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

2.  In vivo efficacy of aerosolized nanostructured itraconazole formulations for prevention of invasive pulmonary aspergillosis.

Authors:  Barbara J Hoeben; David S Burgess; Jason T McConville; Laura K Najvar; Robert L Talbert; Jay I Peters; Nathan P Wiederhold; Bradi L Frei; John R Graybill; Rosie Bocanegra; Kirk A Overhoff; Prapasri Sinswat; Keith P Johnston; Robert O Williams
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

Review 3.  Beyond tissue concentrations: antifungal penetration at the site of infection.

Authors:  Yanan Zhao; Brendan Prideaux; Shane Baistrocchi; Donald C Sheppard; David S Perlin
Journal:  Med Mycol       Date:  2019-04-01       Impact factor: 4.076

4.  Posaconazole-Loaded Leukocytes as a Novel Treatment Strategy Targeting Invasive Pulmonary Aspergillosis.

Authors:  Shane R Baistrocchi; Mark J Lee; Melanie Lehoux; Benjamin Ralph; Brendan D Snarr; Robert Robitaille; Donald C Sheppard
Journal:  J Infect Dis       Date:  2017-06-01       Impact factor: 5.226

5.  Efficacy of Voriconazole against Aspergillus fumigatus Infection Depends on Host Immune Function.

Authors:  Emily E Rosowski; Jiaye He; Jan Huisken; Nancy P Keller; Anna Huttenlocher
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191

6.  Assessment of efficacy of antifungals against Aspergillus fumigatus: value of real-time bioluminescence imaging.

Authors:  Célimène Galiger; Matthias Brock; Grégory Jouvion; Amélie Savers; Marianna Parlato; Oumaïma Ibrahim-Granet
Journal:  Antimicrob Agents Chemother       Date:  2013-04-15       Impact factor: 5.191

7.  Antifungal therapy of murine Aspergillus terreus infection.

Authors:  John R Graybill; Steve Hernandez; Rosie Bocanegra; Laura K Najvar
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

8.  Aspergillus fumigatus inhibits angiogenesis through the production of gliotoxin and other secondary metabolites.

Authors:  Ronen Ben-Ami; Russell E Lewis; Konstantinos Leventakos; Dimitrios P Kontoyiannis
Journal:  Blood       Date:  2009-10-20       Impact factor: 22.113

9.  Susceptibility breakpoints for amphotericin B and Aspergillus species in an in vitro pharmacokinetic-pharmacodynamic model simulating free-drug concentrations in human serum.

Authors:  A Elefanti; J W Mouton; P E Verweij; L Zerva; J Meletiadis
Journal:  Antimicrob Agents Chemother       Date:  2014-02-10       Impact factor: 5.191

10.  Proangiogenic growth factors potentiate in situ angiogenesis and enhance antifungal drug activity in murine invasive aspergillosis.

Authors:  Ronen Ben-Ami; Nathaniel D Albert; Russell E Lewis; Dimitrios P Kontoyiannis
Journal:  J Infect Dis       Date:  2013-01-09       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.